Bente Lund

Medicine & Life Sciences

1. Ovarian Neoplasms 100%
2. niraparib 74%
3. Platinum 69%
4. liposomal doxorubicin 50%
5. Ovarian Epithelial Carcinoma 47%
6. Bevacizumab 37%
7. Drug Therapy 35%
8. Panitumumab 29%
9. Progression-Free Survival 26%
10. Patient Reported Outcome Measures 19%
11. Placebos 19%
12. Quality of Life 18%
13. selinexor 18%
14. Survival 17%
15. Carboplatin 16%
16. titanium nickelide 16%
17. Combination Drug Therapy 16%
18. nintedanib 16%
19. Therapeutics 15%
20. Neoplasms 14%
21. Equivalence Trials 13%
22. Cytoreduction Surgical Procedures 13%
23. Cell Nucleus Active Transport 11%
24. gemcitabine 11%
25. Vagina 11%
26. Prostate 10%
27. Multicenter Studies 9%
28. Prostatic Neoplasms 9%
29. Uterine Cervical Neoplasms 9%
30. Radiotherapy 8%
31. Stents 8%
32. Melanoma 8%
33. Paclitaxel 8%
34. Randomized Controlled Trials 7%
35. Safety 7%
36. Germ-Line Mutation 6%
37. Mutation 6%
38. Confidence Intervals 6%
39. Disease Progression 5%
40. Intention 5%
41. Random Allocation 5%
42. Homologous Recombination 5%
43. Conformal Radiotherapy 5%